NovMetaPharma Amends Capital Increase Details
노브메타파마
229500
Signal Score
Historical Avg Return (5d)
+0.28%
Data Coverage
100%n=2398
Risk-adjusted indicator based on 2398 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares (Amended): 148,933 Shares (Previously 158,862 Shares)
- • Funding Size (Amended): 1,049,977,650 KRW (Previously 1,119,977,100 KRW)
- • Funding Purpose: Operating Funds
- • Lead Investor: NH Investment & Securities (70,921 Shares)
AI Analysis Summary
NovMetaPharma Co., Ltd. announced an amendment to its paid-in capital increase. The number of new shares to be issued has been adjusted from 158,862 to 148,933, resulting in a reduced funding size from 1,119,977,100 KRW to 1,049,977,650 KRW. The funds are designated for operating expenses in 2026. The change primarily involves the removal of one third-party allottee, Kim Jong-yoon. While the dilution is slightly less than initially planned, it still represents an increase in outstanding shares, which could be a minor negative for existing shareholders.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.